Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | DAO | P14920 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254745 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| Hydrochloric Acid SCHEMBL30164372 | 0.98 | KDM4E (0.68) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| Hydrochloric Acid SCHEMBL27979417 | 0.98 | KDM4E (0.68) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL30884907 | 0.88 | KDM4E (0.64) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL7877575 | 0.84 | KDM4E (0.59) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL31081137 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL721792 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| Hydrochloric Acid SCHEMBL7882333 | 0.83 | KDM4E (0.57) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL4739061 | 0.83 | KDM4E (0.66) | KDM4EALDH1A1GAAMAPK1NPC1 | |
| SCHEMBL23331084 | 0.82 | FLT3 (0.70) | KDM4EALDH1A1GAAMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107419-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | KDM4E 1602/4885ALDH1A1 2152/4885GAA 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.